On a reported basis, sales fell 97.1% from KRW 471.3 billion in 2022 to KRW 13.8 billion in 2023. That drop followed the surge in COVID-19 test kit exports, when 2021 consolidated sales reached KRW 321.8 billion, up 604.0% year on year, according to a March 2022 technical analysis report.
Sales then rose 83.8% to KRW 25.4 billion in 2024 and 18.5% to KRW 30.1 billion in 2025, two consecutive years of increases after the 2023 low, though the level remains far below 2022.
The operating margin fell from 45.6% in 2022 to -378.6% in 2023, when the operating loss of KRW 52.4 billion suggests that fixed costs weighed more heavily than the sales decline alone.
The margin improved to -41.5% in 2024 and -35.0% in 2025, but the company has recorded losses for three consecutive years from 2023 to 2025.
The net loss attributable to controlling shareholders narrowed from KRW 55.4 billion in 2023 to KRW 30.4 billion in 2024 and KRW 15.6 billion in 2025, while the net loss including non-controlling interests was KRW 55.4 billion, KRW 35.6 billion and KRW 21.7 billion over the same years.
The two figures differ because non-controlling interests are included in the latter. Operating cash flow swung from negative KRW 55.5 billion in 2023 to positive KRW 25 billion in 2024 and KRW 10.1 billion in 2025.
Quarterly results show a sharp volatility: the third quarter of 2025 posted sales of KRW 8.65 billion, an operating loss of KRW 2.45 billion and a profit attributable to controlling shareholders of KRW 679 million, but the fourth quarter swung to a net loss of KRW 8.53 billion on sales of KRW 6.42 billion.
Sales peaked at KRW 8.92 billion in the first quarter of 2026, when the company returned to a profit of KRW 3.47 billion attributable to controlling shareholders.
Sales then declined to KRW 7.74 billion in the second quarter, with a net loss of KRW 11.2 billion, and to KRW 5.66 billion in the third quarter, with an operating loss of KRW 3.47 billion and a net loss of KRW 1.7 billion.
Over the last four quarters the net loss attributable to controlling shareholders totals KRW 18 billion, and whether the first-quarter profit repeats is the next checkpoint for the company's quarterly earnings.